Results 51 to 60 of about 3,066 (203)

Effect of Elagolix Exposure on Clinical Efficacy End Points in Phase III Trials in Women With Endometriosis‐Associated Pain: An Application of Markov Model

CPT: Pharmacometrics & Systems Pharmacology, 2020
Elagolix is an oral gonadotropin‐releasing hormone antagonist approved by the US Food and Drug Administration (FDA) for the management of moderate‐to‐severe pain associated with endometriosis and in combination with estradiol/norethindrone acetate ...
Insa Winzenborg, Akshanth R. Polepally, Ahmed Nader, Nael M. Mostafa, Peter Noertersheuser, Juki Ng   +5 more
doaj   +1 more source

Effect of Zhuyun I Recipe Capsule Enema on the Immune Microenvironment of the Endometrium during Implantation Window in Rats

Emergency Medicine International, 2022
Background. Preterm birth is the leading cause of neonatal death, and there are no effective clinical means for the prevention and treatment of spontaneous preterm birth, mainly because the mechanism for labor initiation has not been fully elucidated ...
Hang Zhou, Pei Guo, Pengfei Zeng, Zhixing Yin, Li Yan, Jinzhu Huang, Yi Wang, Juan Li, Wanting Xia, Yang Wang, Chang Liu, Qian Zeng   +11 more
doaj   +1 more source

Update on Menopause Hormone Therapy; Current Indications and Unanswered Questions

Clinical Endocrinology, EarlyView.
ABSTRACT Objective To provide clinicians involved in managing menopause with a summary of current evidence surrounding menopause hormone therapy (MHT). Design The authors evaluate and synthesize existing pooled evidence relating to MHT's clinical indications, efficacy, and safety and explore the limitations of existing data. Patients The review focuses
Annice Mukherjee, Susan R. Davis
wiley   +1 more source

Integrating transcriptomics and network analysis-based multiplexed drug repurposing to screen drug candidates for M2 macrophage-associated castration-resistant prostate cancer bone metastases

Frontiers in Immunology, 2022
Metastatic castration-resistant prostate cancer (CRPC) has long been considered to be associated with patient mortality. Among metastatic organs, bone is the most common metastatic site, with more than 90% of advanced patients developing bone metastases (
Jinyuan Chang, Zhenglong Jiang, Tianyu Ma, Jie Li, Jiayang Chen, Peizhi Ye, Li Feng   +6 more
doaj   +1 more source

A phase 1 study of the breast milk and plasma pharmacokinetics of zavegepant 10 mg intranasal dose in healthy lactating women

Headache: The Journal of Head and Face Pain, Volume 66, Issue 5, Page 1050-1057, May 2026.
Abstract Objective This study evaluated the pharmacokinetics of zavegepant in human breast milk and plasma following a single, 10 mg dose of zavegepant nasal spray. Background Zavegepant nasal spray is a member of the gepant class of medications; small molecule inhibitors of the calcitonin gene‐related peptide receptor.
Abhijeet Jakate, Yan Weng, Ani Shkrodova, Ogert Fisniku, Ding Ding, Kayce Morton, Benjamin Maligalig, Pamela Garnick, Jing Liu, Mohamed H. Shahin   +9 more
wiley   +1 more source

Potential of Typha angustifolia L. in removing norethindrone from water [PDF]

, 2018
Uncontrollable demand of pharmaceutical especially contraception drugs and poor performance of conventional wastewater treatment plants has resulted in the increasing concentration of pharmaceutical residues in natural environment.
Lee, Jie-Yinn, Vairappan, Charles Santhanaraju, Kartini Saibeh   +2 more
core  

Treatment of symptomatic rectovaginal endometriosis with an estrogen-progestogen combination versus low-dose norethindrone acetate

, 2005
Objective: To evaluate the efficacy, safety, and tolerability of an estrogen-progestogen combination versus low-dose norethindrone acetate in the treatment of persistent pain after surgery for symptomatic rectovaginal endometriosis.
O. De Giorgi, G. Pietropaolo, P.G. Crosignani, R. Pasin, P. Vercellini, A. Chiodini   +5 more
core   +1 more source

Combined Continuous Ethinyl Estradiol/Norethindrone Acetate Does Not Improve Forearm Blood Flow in Postmenopausal Women at Risk for Cardiovascular Events: A Pilot Study [PDF]

, 2007
Objective: This study sought to determine whether combined continuous ethinyl estradiol and norethindrone acetate, a postmenopausal hormone therapy (HT) combination designed to have fewer side effects than cyclical therapies and therapies using ...
Rose, Patricia A., Brook, Robert D., Kehrer, Christine, Duvernoy, Claire S., Kim, H. Myra   +4 more
core   +1 more source

A concept for a new approach to combined oral contraception from adolescence to perimenopause: Continuous use of the oral GnRH antagonist Relugolix and the fetal estrogen Estetrol

Acta Obstetricia et Gynecologica Scandinavica, Volume 105, Issue 4, Page 568-574, April 2026.
It is expected that the relugolix estetrol combination RE4W will enable women to control their fertility and prevent menstrual cycle related problems, while offering a smooth transition through perimenopause into the postmenopause and decrease the risk of breast cancer.
Herjan J. T. Coelingh Bennink, Karolina Afors, Luis Bahamondes, Alessandra Graziottin, Deborah Bateson, Teresa Bombas, Yutaki Osuga, Santiago Palacios, Carolyn L. Westhoff, Kristina Gemzell‐Danielsson   +9 more
wiley   +1 more source

Compound Library Screening Identified Cladribine as a Novel Radiosensitizer for Prostate Cancer

Cancer Science, Volume 117, Issue 4, Page 1136-1147, April 2026.
The combination of cladribine and irradiation significantly suppressed the growth of DU145‐derived tumors compared with the DMSO plus irradiation group in the mouse model. In addition, it also elevated the percentage of γH2AX‐positive cells after irradiation.
Toshiki Oka, Koji Hatano, Shohei Katsuki, Tomohiro Kanaki, Shunsuke Inoguchi, Masaru Tani, Akihiro Yoshimura, Yuki Horibe, Yutong Liu, Nesrine Sassi, Yohei Okuda, Akinaru Yamamoto, Toshihiro Uemura, Gaku Yamamichi, Yu Ishizuya, Takuji Hayashi, Yoshiyuki Yamamoto, Taigo Kato, Atsunari Kawashima, Keisuke Tamari, Bangzhong Lin, Akiyoshi Tani, Kazutake Tsujikawa, Yutaka Takahashi, Kazuhiko Ogawa, Shawn E. Lupold, Norio Nonomura   +26 more
wiley   +1 more source